Suvorexant and Lemborexant exhibit fruitful results for delirium in critically ill adult patients

Written By : Dr.Niharika Harsha B |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-11-14T09:45:04+05:30 | Updated On 14 Nov 2022 1:55 PM IST

A recent study found that Suvorexant and Lemborexant may be effective in preventing delirium in critically ill adult patients in an advanced critical care center. The study results were published in The Journal of Clinical Psychiatry.

Delirium is a syndrome that is characterized by an acute onset of deficits in attention, awareness, and cognition that fluctuate in severity over a short period. It is a common symptom in critically ill patients in the intensive care unit. Literature shows that suvorexant and lemborexant are the dual orexin receptor antagonists (DORAs) which are used for sleep disturbances can also be used to prevent delirium in critically ill patients. Hence researchers conducted an observational study in the advanced emergency and critical care center at Saga University Hospital to understand the efficacy of suvorexant and lemborexant in preventing delirium in critically ill patients.

Also Read: Simvastatin fails as a disease-modifying treatment for Parkinson's disease patients: JAMA

Patients 18 years of age or older who were admitted to the emergency center between July 2018 and November 2021 with a hospitalization duration of at least 72 h were included in the study. Kaplan-Meier curves and log-rank tests were performed to compare patients with and without DORA treatment. Cox regression analyses adjusting for factors associated with delirium risk were also performed.

Results:

Out of the 633 enrolled patients, 82 were treated with suvorexant and 41 with lemborexant.
The hazard ratios for the development of delirium were 0.56 for patients treated with suvorexant and 0.26 for those treated with lemborexant as per the cox regression analysis without any adjustment.
After adjustment for delirium risk factors, the hazard ratios remained low at 0.34 (0.20–0.58) for suvorexant and 0.21 (0.08–0.52) for lemborexant.

Also Read: Subclinical hyperthyroidism significantly associated with increased fracture risk: JAMA

This study is the first of its kind to suggest that both suvorexant and lemborexant may have a preventive effect against delirium in critically ill patients requiring intensive care in an emergency department.

Further reading: Matsuoka A, Tobita S, Sogawa R, et al. Evaluation of suvorexant and lemborexant for the prevention of delirium in adult critically ill patients at an advanced critical care center: a single-center, retrospective, observational study. J Clin Psychiatry. 2023;84(1):22m14471. https://doi.org/10.4088/JCP.22m14471

dual orexin receptor antagonistsDORAsuvorexantlemborexantdeliriumintensive care unitneuropeptideOrexinsleep disturbances

Source : The Journal of Clinical Psychiatry

Dr.Niharika Harsha B

BDS, MDS

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751